Author:
Saglimbene Valeria,Palmer Suetonia C.,Ruospo Marinella,Natale Patrizia,Maione Ausilia,Nicolucci Antonio,Vecchio Mariacristina,Tognoni Gianni,Craig Jonathan C.,Pellegrini Fabio,Lucisano Giuseppe,Hegbrant Jörgen,Ariano Rosario,Lamacchia Olga,Sasso Antonio,Morano Susanna,Filardi Tiziana,De Cosmo Salvatore,Pugliese Giuseppe,Procaccini Deni A.,Gesualdo Loreto,Palasciano Giuseppe,Johnson David W.,Tonelli Marcello,Strippoli Giovanni F.M.,
Abstract
BackgroundThe comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.MethodsIn a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP<130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, doubling of serum creatinine, albuminuria, eGFR, BP, and adverse events.ResultsBecause of slow enrollment, the trial was modified and stopped 41% short of targeted enrollment of 2100 participants, corresponding to 35% power to detect a 25% reduced risk in the primary outcome. Our analysis included 1243 adults, with median follow-up of 2.7 years. Efficacy outcomes were similar between groups (ACE inhibitor versus ARB, ACE inhibitor versus combination, ARB versus combination) as were rates of serious adverse events. The rate of permanent discontinuation for ARB monotherapy (6.3%) was significantly lower than for ACE inhibitor monotherapy (15.7%) or combined therapy (18.3%).ConclusionsPatients may tolerate ARB monotherapy better than ACE inhibitor monotherapy. However, data from this trial and similar trials, although as yet inconclusive, show no trend suggesting differences in mortality and renal outcomes with ACE inhibitors or ARBs as dual or monotherapy in patients with albuminuria and diabetes or other cardiovascular risk factors.
Publisher
American Society of Nephrology (ASN)
Subject
Nephrology,General Medicine
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献